Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on August 11, 2014. The report serves to announce the company's financial results for the three and six months ended June 30, 2014. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not detailed within the body of this 8-K document.
Material Changes
No specific material changes versus prior periods are quantified in this filing. The document solely references the issuance of the press release containing the comparative financial results.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the information is furnished but not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 11, 2014) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate based on the six-month data in the press release.
- Confirm the status of the company's clinical development programs mentioned in the full press release.
- Note that the 8-K itself does not constitute a filed financial statement under Section 18 of the Exchange Act.